Quantum Biopharma (QNTM) Cash from Financing Activities (2019 - 2026)

Quantum Biopharma has reported Cash from Financing Activities for 6 years, with the latest figure at $7.0 million in Q1 2026.

• Quarterly Cash from Financing Activities rose 123.35% year-over-year to $7.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.0 million (down 29.75% YoY) and the FY2025 annual result came in at $6.1 million, down 47.51% from the prior year.
• Cash from Financing Activities improved to $7.0 million in Q1 2026 per QNTM's latest filing, from $1.4 million in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $7.0 million in Q1 2026 and troughed at -$4.1 million in Q4 2022.
• A 4-year average of $1.7 million and a median of $1.4 million in 2025 frame the typical range for Cash from Financing Activities.
• The widest YoY moves for Cash from Financing Activities: up 450.97% in 2025, down 96.12% in 2025.
• Over 4 years, Cash from Financing Activities stood at -$4.1 million in 2022, then surged by 160.34% to $2.5 million in 2024, then plunged by 42.68% to $1.4 million in 2025, then jumped by 394.82% to $7.0 million in 2026.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered $7.0 million, $1.4 million, and $261425.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.